A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00913757|
Recruitment Status : Recruiting
First Posted : June 4, 2009
Last Update Posted : October 19, 2017
- Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States.
- More information is needed about the causes and effects of liver cancer, and further research into individuals who are at high risk for developing liver cancer is needed for early diagnosis and prevention.
- To identify genetic factors that may help to explain the aggressiveness of liver cancer.
- To determine if HCC biomarkers exist in blood, urine, and tissue samples.
- Patients between the ages of 18 and 90 who have been diagnosed with HCC or have a high risk for developing HCC because of fatty liver disease (alcohol-related or non-alcohol-related) or chronic hepatitis B or C.
- Participants will reside in Baltimore City and the surrounding areas.
- Participants will complete a questionnaire and provide blood and urine samples for testing:
- The questionnaire will include questions about individual and family medical history, tobacco use, and exposure to known factors for liver cancer.
- Blood and urine samples will be collected from all participants after the questionnaire.
- Tumor tissue and healthy tissue will be collected from selected participants if they undergo surgery for their cancer or disease.
- No specific treatment will be offered as part of this protocol, but participants have the option to be treated under different protocols.
|Condition or disease|
|Carcinoma, Hepatocellular Liver Cirrhosis, Alcoholic Hepatitis, Alcoholic Hepatitis, Chronic Hepatitis, Viral, Human|
Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver with rising incidence in the United States. HCC patients have a dismal outcome and are an underserved cancer population. We are proposing a liver cancer case-control and case-case study to be conducted in Baltimore, Maryland.
Our research is aimed to identify genetic and genomic changes that might explain the aggressive nature of liver cancer. We will test the primary hypothesis that HCC biomarkers exist in blood products (or mouth wash), urine and/or tissues that can be used for early diagnosis and prevention. A unique study factor is the use of urine samples for biomarker identification. A secondary goal will be to examine whether certain genetic and genomic factors modify liver cancer susceptibility using candidate and genome wide association study approaches. Although other studies have investigated genetic susceptibility, large scale studies have not been conducted for liver cancer. Our study will also be valuable due to access to frozen tumor specimens from pre-therapy resection, whose collection is required for gene expression analysis. If certain genes are related to HCC risk and progression, this tissue resource will be used to further validate our findings with laboratory investigations. The proposed study is designed to be exploratory and hypothesis generating.
The participants will reside in Baltimore City and surrounding areas. Cases will have pathologically confirmed liver cancer or risk factors for HCC development. Risk factors include chronic liver disease due to hepatitis B and/or C viral infection, nonalcoholic steatohepatitis or alcoholic cirrhosis. The study will be supported by an epidemiological infrastructure developed by our University of Maryland School of Medicine resource contractor for ongoing lung and prostate cancer case-control studies. The enrollment of controls will begin concurrently with case accrual, and will continue for 5 years. Population-based controls will be recruited using a triple eligibility criterion, such that controls eligible for the lung/prostate study will be asked to complete a supplemental questionnaire for the liver study.
The study will include 400 primary HCC cases, 800 patients with chronic liver disease (high risk non-cancer cases) and a sample of 800 population-based controls. The HCC and high risk non-cancer cases will be recruited at two Baltimore hospitals, the Veterans Affairs Medical Center, and the University of Maryland School of Medicine over a period of 13-15 years. Controls will be identified through a Department of Motor Vehicle database and match cases by age, gender, race and county of residency. The study will involve administration of a questionnaire and collection of blood (or mouth wash) from all study subjects. Fresh-frozen tumor and tumor surrounding non-cancerous specimens will be obtained from approximately 20 percent of the cancer patients. The cases will receive one questionnaire.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area|
|Study Start Date :||July 1, 2009|
- Large-scale molecular profiling study to identify HCC biomarkers for early diagnosis and prevention. [ Time Frame: ongoing ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913757
|Contact: Dean L. Mann, M.D.||(410) email@example.com|
|Contact: Xin Wang, M.D.||(240) firstname.lastname@example.org|
|United States, Maryland|
|University of Maryland Medical Center||Recruiting|
|Baltimore, Maryland, United States|
|Veterans Affairs Medical Center||Recruiting|
|Baltimore, Maryland, United States|
|Principal Investigator:||Xin Wang, M.D.||National Cancer Institute (NCI)|